Selected article for: "antiviral agent and present study"

Author: Milne, George J; Baskaran, Pravin; Halder, Nilimesh; Karl, Stephan; Kelso, Joel
Title: Pandemic influenza in Papua New Guinea: a modelling study comparison with pandemic spread in a developed country
  • Document date: 2013_3_26
  • ID: y01w04lc_124
    Snippet: The interventions used in the present study are based on social distancing. Surveys have shown that a higher proportion of low-income countries have social distancing interventions planned in the case of a pandemic, compared to high income European countries due to their feasibility and cost-effectiveness. Pharmaceutical-based interventions were not considered in this study due to cost and delivery issues found with low-income countries. [4, 8] C.....
    Document: The interventions used in the present study are based on social distancing. Surveys have shown that a higher proportion of low-income countries have social distancing interventions planned in the case of a pandemic, compared to high income European countries due to their feasibility and cost-effectiveness. Pharmaceutical-based interventions were not considered in this study due to cost and delivery issues found with low-income countries. [4, 8] Consideration may need to be given to some form of antiviral agent use, possibly for case treatment, given the poor performance of purely social distancing interventions in developing countries as suggested by this study. The advantage of antiviral use is that it may be targeted at reducing within-household transmission, a location of transmission otherwise not impacted by social distancing interventions. The present study shows that larger numbers of transmissions occur within households due to the larger household sizes in countries such as PNG. Furthermore, low-income countries generally have population health profiles not seen in developed countries, including the prevalence of diseases such as malaria, tuberculosis and HIV. [44] Antiviral treatment of influenza cases co-infected with such diseases may be an appropriate intervention strategy given the poorer health outcomes which co-morbidity may impose. [12] The provision and use of antiviral agents will have challenges not faced by industrialised countries, due to the cost of providing an antiviral stockpile and subsequent distribution of antivirals in countries which have health systems already stretched to capacity. [15] The importance of suitable pandemic influenza preparedness plans for low-income countries is recognized by the WHO [45, 46] . Disease transmission models will play a role in guiding policy makers in determining the effectiveness of possible pandemic countermeasures. History tells us that low-income countries are likely to be more affected, yet almost all models deal with mitigation strategies for developed nations with good health infrastructure and low prevalence of endemic diseases. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 Daily case incidence for the no intervention, school closure and rigorous social distancing (school closure and workplace and community contact reductions) scenarios is shown. The blue, red and green curves represent the Albany, Madang and Madang-nnh models respectively.

    Search related documents:
    Co phrase search for related documents
    • antiviral agent and case treatment: 1, 2, 3, 4, 5, 6
    • antiviral agent and co morbidity: 1, 2, 3
    • antiviral agent and co morbidity impose: 1, 2, 3
    • antiviral agent and community contact: 1
    • antiviral agent and community contact workplace: 1
    • antiviral agent and cost effectiveness: 1, 2, 3
    • antiviral agent and cost effectiveness feasibility: 1, 2
    • antiviral agent and daily case: 1
    • antiviral agent and daily case incidence: 1
    • antiviral agent and delivery cost: 1, 2, 3, 4, 5
    • antiviral agent and distancing intervention: 1
    • antiviral agent and endemic disease: 1
    • antiviral agent and good health infrastructure: 1, 2
    • antiviral agent and health infrastructure: 1, 2
    • antiviral agent and health system: 1
    • antiviral agent and high income: 1, 2, 3, 4, 5
    • antiviral agent and HIV tuberculosis: 1, 2, 3
    • antiviral agent and HIV tuberculosis malaria: 1, 2, 3
    • antiviral agent and low income: 1, 2, 3, 4, 5, 6